Company intelligence / Profile preview
CelSiege Biosciences
Hsinchu, Taiwancelsiege.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CelSiege Biosciences is a biotechnology company specializing in the development of a novel "Cell-in-Cell" (CiC) platform for the treatment of solid tumors. Their proprietary technology acts as a "Trojan Horse," utilizing carrier cells to protect and deliver therapeutic effector cells, such as NK cells or CAR-T cells, directly into the immunosuppressive tumor microenvironment. By overcoming the physical and chemical barriers of solid tumors, CelSiege aims to enhance the efficacy and infiltration of cell therapies. The company is currently in the pre-clinical stage, focusing on optimizing its delivery system for various oncology indications.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyNK cell therapyCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on CelSiege Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CelSiege Biosciences.